Volume 20, Issue 3

Drug-induced mucosal injury (DIMI) of the gastrointestinal (GI) tract can be a major clinical challenge because most agents can cause a variety of clinical, endoscopic and histological patterns of damage while a recognisable pattern of GI injury is rarely specific for a particular drug.

Dear Y-ECCO Friends, Now that the sun is setting on the summer, I hope that everyone has enjoyed a break with friends and family. The Y-ECCO Committee was delighted to host the 3rd Y-ECCO Mentorship Forum in Vienna in June. While we retain the same format each year, rotation of the faculty and delegates means that the forum is always different. We were again supported by many senior members of the ECCO Family, who kindly gave up their time, and the meeting was once more a great occasion and a fine opportunity to come together outside of the congress.

Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. Nature 2025;642:458-66. doi: 10.1038/s41586-025-08940-0

Noninvasive, microbiome-based diagnosis of inflammatory bowel disease Zheng J, Sun Q, Zhang M, et al. Nature Medicine 2024;30:3555–67. https://doi.org/10.1038/s41591-024-03280-4

Preclinical protein signatures of Crohn’s disease and ulcerative colitis: A nested case-control study within large population-based cohorts Grännö O, Bergemalm D, Salomon B, et al. Gastroenterology 2025;168:741–53. doi: 10.1053/j.gastro.2024.11.006

Luisa Avedano is widely recognised within the IBD Community as a leading voice for patient representation. She currently serves as CEO of the International European Federation of Crohn’s and Ulcerative Colitis Associations (IFCCA), formerly known as EFCCA, based in Brussels. In this edition of the Y-ECCO Interview Corner, we are honoured to speak with Luisa and gain insights from her inspiring work, her perspectives on IBD research and her knowledge of the vital role that patients play as active contributors to science.